Core Viewpoint - Izotropic Corporation held its Annual General and Special Meeting on December 29, 2025, where key corporate matters were approved by shareholders [1][2]. Group 1: Meeting Outcomes - All nominees for the board of directors were approved, maintaining the number of directors at five [3]. - The re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP was approved [3]. - An amendment to the Company's By-Laws was made to reduce the quorum requirement from 20% to at least 1% of the issued voting shares, while decisions will still require majority approval. This change addresses challenges faced by public companies, such as mail delays and disruptions in receiving voting packages [3]. Group 2: Shareholder Engagement - The Company expressed gratitude to all shareholders for their participation and ongoing support [4]. Group 3: Company Information - Izotropic Corporation focuses on innovative medical technologies and imaging products for breast cancer screening, diagnosis, and treatment [1]. - Additional information about the Company can be found on its corporate website and educational platform [5].

Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and OutlookOctober 23, 2025 8:00 AM EDT | Source: Izotropic CorporationVancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast ca ...

Izotropic Gains Visibility as AI Market Broadens Beyond TechSeptember 10, 2025 1:24 PM EDT | Source: Izotropic CorporationVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces ...

Izotropic Announces Non-Brokered Private Placement & Extends WarrantsAugust 26, 2025 8:00 AM EDT | Source: Izotropic CorporationVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announ ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available ...